Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug
Synopsis
- Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
- This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
Eli Lilly and Company (LLY) on Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to lower pricing for its popular weight-loss drug Zepbound, available through its digital health platform LillyDirect.
Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November, the company said. This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay at Walmart pharmacies, the company said.
Zepbound, containing Tirzepatide, reduces appetite and the amount a person eats to induce weight loss. Lilly started offering Zepbound at discounted prices to cash-paying customers on LillyDirect in June to expand access.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.